1 |
Khachaturian, Z. S. : Diagnosis of Alzhemier's disease. Arch. Neurol. 42, 1097 (1985)
DOI
ScienceOn
|
2 |
Cottingham, M. G., Voskuil, J. L. and Vaux, D. J. : The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers. Biochemistry 42, 10863 (2003)
DOI
ScienceOn
|
3 |
Prous, J., Rabasseda, X. and Castaner, J. : SDZ-ENA-713 cognition enhancer acetylcholinesterase inhibitor. Drugs Future 19, 656 (1996)
|
4 |
De Ferrari, G. V., Canales, M. A., Shin, I., Weiner, L. M., Silman, I. and Inestrosa, N. C. : A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 40, 10447 (2001)
DOI
ScienceOn
|
5 |
Sugimoto, H. : Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem. Rec. 1, 63 (2001)
DOI
ScienceOn
|
6 |
Barril, X., Orozco, M. and Luque, F. J. : Towards improved acetylcholinesterase inhibitors: a structural and computational approach. Mini. Rev. Med. Chem. 1, 255 (2001)
DOI
ScienceOn
|
7 |
Luhrs, T., Ritter, C., Adrian, M., Riek-Loher, D., Bohrmann, B., Dobeli, H., Schubert, D. and Riek, R. : 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. USA 102, 17342 (2005)
|
8 |
Massi, F. and Straub, J. E. : Structural and dynamical analysis of the hydration of the Alzheimer's beta-amyloid peptide. J. Comput. Chem. 24, 143 (2003)
DOI
ScienceOn
|
9 |
Santini, S., Mousseau, N. and Derreumaux, P. : In silico assembly of Alzheimer's Abeta16-22 peptide into beta-sheets. J. Am. Chem. Soc. 126, 11509 (2004)
DOI
ScienceOn
|
10 |
Greig, N. H., Sambamurti, K., Yu, Q. S., Brossi, A., Bruinsma, G. B. and Lahiri, D. K. : An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr. Alzheimer Res. 2, 281 (2005)
DOI
ScienceOn
|
11 |
Selkoe, D. J. : Translating cell biology into therapeutic advances in Alzhemier's disease. Nature 399, A23 (1999)
DOI
ScienceOn
|
12 |
Lilienfeld, S. : Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 8, 159 (2002)
DOI
ScienceOn
|
13 |
Kurz, A. : The therapeutic potential of tacrine. J. Neural Transm. Suppl. 54, 295 (1998)
|
14 |
Petkova, A. T., Ishii, Y., Balbach, J. J., Antzutkin, O. N., Leapman, R. D., Delaglio, F. and Tycko, R. : A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints fromsolid state NMR. Proc. Natl. Acad. Sci. USA 99, 16742 (2002)
|
15 |
Patrice, T. : -Amyloid aggregation inhibitors for Treatment of Alzheimer's disease: Dream or Reality- Mini Reviews in Medicinal Chemistry 1, 175 (2001)
DOI
ScienceOn
|
16 |
Clarimon, J., Bertranpetit, J., Calafell, F., Boada, M., Tarraga, L. and Comas, D. : Association study between Alzheimer's disease and genes involved in Abeta biosynthesis, aggregation and degradation: suggestive results with BACE1. J. Neurol. 250, 956 (2003)
DOI
ScienceOn
|
17 |
Pietrzik, C. and Behl, C. : Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int. J. Exp. Pathol. 86, 173 (2005)
DOI
ScienceOn
|
18 |
Silverberg, G. D., Mayo, M., Saul, T., Carvalho, J. and McGuire, D. : Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers. Expert. Rev. Neurother. 4, 97 (2004)
DOI
ScienceOn
|
19 |
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A. and Klein, W. L. : Alzheimer's disease-affected brain: presence of oligomeric A-beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100, 10417 (2003)
|
20 |
Cottingham, M. G., Hollinshead, M. S. and Vaux, D. J. : Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry 41, 13539 (2002)
DOI
ScienceOn
|
21 |
Jann, M. W. : Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20, 1 (2000)
DOI
ScienceOn
|
22 |
Zarotsky, V., Sramek, J. J. and Cutler, N. R. : Galantamine hydrobromide: an agent for Alzheimer's disease. Am. J. Health Syst. Pharm. 60, 446 (2003)
|
23 |
Hollander, E., Mohs, R. C. and Davis, K. L. : Cholinergic approaches to the treatment of Alzheimer's disease. Br. Med. Bull. 142, 97 (1986)
|